Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for pulmonary systemic sclerosis has been reported in the published literature.
1 FDA-approved treatment is available for pulmonary systemic sclerosis, including TOCILIZUMAB (AVTOZMA, approved 2025).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
3 clinical trials registered. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE3, 2 PHASE2. Research is sponsored by a mix of industry and academic institutions.
206 publications have been identified in PubMed for pulmonary systemic sclerosis. Kisho has analyzed 147 by research type. Research spans Review / Meta-Analysis (36%), Epidemiology / Natural History (20%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 53 |
Data assembled from 4 of 12 sources · Last updated Nov 17, 2026, 11:08 AM UTC
TOCILIZUMAB |
— |
2025 |
Available |
Gene therapy approaches for pulmonary systemic sclerosis have been reported in the published literature.
3 trials found
36%
Disease patterns and progression | 29 | 20% |
Laboratory research | 25 | 17% |
Clinical study results | 15 | 10% |
Testing and diagnosis research | 14 | 10% |
Other research | 4 | 3% |
Patient case studies | 4 | 3% |
New treatment approaches | 3 | 2% |
Eshagh D (2026). [PMID: 41451470](https://pubmed.ncbi.nlm.nih.gov/41451470/). *Arthritis Rheumatol*. [Clinical Trial Publication]
Kaneko U (2026). [PMID: 40953948](https://pubmed.ncbi.nlm.nih.gov/40953948/). *J Rheumatol*. [Epidemiology / Natural History]
Sakkas LI (2026). [PMID: 40615757](https://pubmed.ncbi.nlm.nih.gov/40615757/). *Clin Rheumatol*. [Review / Meta-Analysis]
Frazier W MD, MPH (2026). [PMID: 42101599](https://pubmed.ncbi.nlm.nih.gov/42101599/). *Am Fam Physician*. [Review / Meta-Analysis]
Hachulla É (2026). [PMID: 40877077](https://pubmed.ncbi.nlm.nih.gov/40877077/). *Rev Med Interne*. [Review / Meta-Analysis]
Lui JK (2026). [PMID: 42112843](https://pubmed.ncbi.nlm.nih.gov/42112843/). *Arthritis Rheumatol*. [Diagnostic / Biomarker]
Buch MH (2026). [PMID: 41936096](https://pubmed.ncbi.nlm.nih.gov/41936096/). *Rheumatology (Oxford)*. [Review / Meta-Analysis]
Huang J (2026). [PMID: 41451447](https://pubmed.ncbi.nlm.nih.gov/41451447/). *Arthritis Rheumatol*. [Basic Science / Preclinical]
Guo R (2025). [PMID: 41388317](https://pubmed.ncbi.nlm.nih.gov/41388317/). *Arthritis Res Ther*. [Epidemiology / Natural History]
Pellicano C (2025). [PMID: 41008604](https://pubmed.ncbi.nlm.nih.gov/41008604/). *Biomolecules*. [Diagnostic / Biomarker]
AI-curated news mentioning pulmonary systemic sclerosis
Updated Oct 23, 2026
Recent studies highlight emerging drugs in phase 2/3 and selected phase 1/2 trials for systemic sclerosis treatment. These developments may offer new therapeutic options for patients suffering from this challenging condition.
The World Scleroderma Congress highlighted emerging paradigms in the understanding and treatment of systemic sclerosis. New research findings may influence future therapeutic strategies for this complex autoimmune disease.
A recent study published in PubMed highlights health literacy levels among individuals with systemic sclerosis, utilizing data from the Scleroderma Patient-Centered Intervention Network (SPIN). This cross-sectional study aims to inform future interventions to improve patient outcomes.